Last10K.com

Unum Therapeutics Inc. (UMRX) SEC Filing 8-K Material Event for the period ending Thursday, March 7, 2019

Unum Therapeutics Inc.

HISTORY TOOLS
CIK: 1622229 Ticker: UMRX

View differences made from one to another to evaluate Unum Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Unum Therapeutics Inc..

Continue

Assess how Unum Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Unum Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Unum Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: UMRX
CIK: 1622229
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-066964
Submitted to the SEC: Thu Mar 07 2019 2:02:08 PM EST
Accepted by the SEC: Thu Mar 07 2019
Period: Thursday, March 7, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/umrx/0001193125-19-066964.htm